STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBNX
  4. [Form 4] Beta Bionics, Inc. Insider Trading Activity

Beta Bionics CPO disposes 1,089 shares in tax-withholding sale

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Beta Bionics insider sale to cover taxes on RSU vesting. Chief Product Officer Mike Mensinger sold 1,089 shares of Beta Bionics common stock on 09/02/2025 at a weighted average price of $18.8632, with the transaction price range between $18.58 and $19.09. After the sale, Mensinger beneficially owned 91,815 shares, reported as direct ownership. The filing states the sale was made to satisfy tax withholding obligations tied to restricted stock unit vesting; no option exercises or derivative transactions were reported. The form was signed by an attorney-in-fact on 09/03/2025.

Positive

  • Sale disclosed as tax withholding for RSU vesting, indicating routine administrative purpose
  • Reporting person retains substantial holdings with 91,815 shares remaining after the sale
  • Form 4 includes price range and weighted average price, improving transparency

Negative

  • Insider sold shares, which some investors may view negatively despite tax-driven rationale

Insights

TL;DR: Small, routine insider sale to cover taxes; not a material change to ownership or control.

The reported disposition of 1,089 shares represents a modest cashless sale associated with RSU vesting rather than a discretionary market sale for liquidity. The weighted average sell price of $18.8632 and post-transaction beneficial ownership of 91,815 shares indicate the reporting person retains a meaningful holding. For most investors, this transaction is neutral because it arises from tax withholding requirements and does not reflect a change in strategic ownership or control.

TL;DR: Compliance-focused disclosure of routine withholding sale; governance implications are minor.

The Form 4 properly discloses an RSU-related sale executed to satisfy tax obligations and includes price range details per SEC staff notice. The filing shows adherence to Section 16 reporting requirements and includes attorney-in-fact signature. There is no indication of related-party issues, unusual timing, or derivative activity, so governance risk is unchanged by this filing.

Insider Mensinger Mike
Role Chief Product Officer
Sold 1,089 shs ($21K)
Type Security Shares Price Value
Sale Common Stock 1,089 $18.8632 $21K
Holdings After Transaction: Common Stock — 91,815 shares (Direct)
Footnotes (1)
  1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. The weighted average sale price for the transaction reported was $18.8632 and the range of prices were between $18.58 and $19.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mensinger Mike
(Last) (First) (Middle)
C/O BETA BIONICS, INC.
11 HUGHES
(Street)
IRVINE CA 92618
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Product Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/02/2025 S(1) 1,089 D $18.8632(2) 91,815 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
2. The weighted average sale price for the transaction reported was $18.8632 and the range of prices were between $18.58 and $19.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
/s/ Stephen Feider, Attorney-in-Fact 09/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Mike Mensinger do according to the Form 4 for BBNX?

He sold 1,089 shares of Beta Bionics common stock on 09/02/2025 to cover tax withholding from RSU vesting.

At what price were the BBNX shares sold?

The weighted average sale price was $18.8632, with the trade price range between $18.58 and $19.09.

How many BBNX shares does Mensinger beneficially own after the transaction?

The Form 4 reports he beneficially owned 91,815 shares following the sale.

Was the sale part of an option exercise or derivative transaction?

No. The filing indicates a non-derivative sale tied to RSU tax withholding and reports no derivative transactions.

Who signed the Form 4 and when?

The Form 4 was signed by Stephen Feider, Attorney-in-Fact on 09/03/2025.